ReviewJournal of lipid research2014
HDL and cholesterol: life after the divorce?
Review in Journal of lipid research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Association of high-density lipoprotein subclasses and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies.European journal of preventive cardiology · 2016Pooled it
- Determinants of high-density lipoprotein (HDL) functions beyond proteome in Asian Indians: exploring the fatty acid profile of HDL phospholipids.Molecular and cellular biochemistry · 2022Trial
- Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib.Circulation · 2018Trial
- Effects of lipid-lowering drugs on high-density lipoprotein subclasses in healthy men-a randomized trial.PloS one · 2014Trial
- Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial.Journal of clinical lipidologyTrial
- Ovarian hormone loss modifies the nucleic acid cargo of circulating extracellular vesicles and skeletal muscle metabolism after acute exercise in rats.Experimental physiology · 2026Article
- Biology of HDL: From Structural Heterogeneity to Dysfunctional Remodeling in Cardiovascular Disease and Comorbidities.Antioxidants (Basel, Switzerland) · 2026Review
- Circulating microRNAs in Body Fluid: "Fingerprint" RNA Snippets Deeply Impact Reproductive Biology.Reproductive sciences (Thousand Oaks, Calif.) · 2025Review
- Extracellular vesicles and nanoparticles at a glance.Journal of cell science · 2024Review
- High-Density Lipoprotein Metabolism and Function in Cardiovascular Diseases: What about Aging and Diet Effects?Nutrients · 2024Review
- Separation of Lipoproteins for Quantitative Analysis ofInternational journal of molecular sciences · 2024Article
- Modulation of the Cellular microRNA Landscape: Contribution to the Protective Effects of High-Density Lipoproteins (HDL).Biology · 2023Review
- Cholesterol Metabolism in Chronic Kidney Disease: Physiology, Pathologic Mechanisms, and Treatment.Advances in experimental medicine and biology · 2022Article
- Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations.Nature reviews. Nephrology · 2021Review
- Changing Perspectives on HDL: From Simple Quantity Measurements to Functional Quality Assessment.Journal of lipids · 2021Review
- Advances in HDL: Much More than Lipid Transporters.International journal of molecular sciences · 2020Review
- Article
- Beta cell secretion of miR-375 to HDL is inversely associated with insulin secretion.Scientific reports · 2019Article
- Non-Exosomal and Exosomal Circulatory MicroRNAs: Which Are More Valid as Biomarkers?Frontiers in pharmacology · 2019Review
- Structural properties of apolipoprotein A-I mimetic peptides that promote ABCA1-dependent cholesterol efflux.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
For decades, HDL and HDL-cholesterol (HDL-C) levels were viewed as synonymous, and modulation of HDL-C levels by drug therapy held great promise for the prevention and treatment of cardiovascular disease. Nevertheless, recent failures of drugs that raise HDL-C to reduce cardiovascular risk and the now greater understanding of the complexity of HDL composition and biology have prompted researchers in the field to redefine HDL. As such, the focus of HDL has now started to shift away from a cholesterol-centric view toward HDL particle number, subclasses, and other alternative metrics of HDL. Many of the recently discovered functions of HDL are, in fact, not strictly conferred by its ability to promote cholesterol flux but by the other molecules it transports, including a diverse set of proteins, small RNAs, hormones, carotenoids, vitamins, and bioactive lipids. Based on HDL's ability to interact with almost all cells and transport and deliver fat-soluble cargo, HDL has the remarkable capacity to affect a wide variety of endocrine-like systems. In this review, we characterize HDL's unique cargo and address the functional relevance and consequences of HDL transport and delivery of noncholesterol molecules to recipient cells and tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.